Articles tagged "Donors, marginal"

2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
M. Sise¹, D. Goldberg², J. Kort³, D. Schaubel⁴, R. Alloway⁵, C. Durand⁶, R. Fontana⁷, J. Friedewald⁸, R. Brown⁹, S. Prenner¹⁰, R. Landis⁴, P. Reese¹¹, R. Chung¹
¹Internal Medicine - Nephrology, MGH, Boston, MA, ²Hepatology and Transplantation, U Miami, Miami, FL, ³Abbvie, Chicago, IL, ⁴Department of Biostatistics, U Penn, Philadelphia, PA, ⁵Department of Internal Medicine - Nephrology and Hypertension, U Cincinnati, Cincinnati, OH, ⁶Department of Medicine, JHU, Baltimore, MD, ⁷Internal Medicine - Gastroenterology, U Michigan, Ann Arbor, MI, ⁸Internal Medicine - Nephrology and Hypertension, Northwestern, Chicago, IL, ⁹Internal Medicine - Hepatology, Weill Cornell, NYC, NY, ¹⁰Internal Medicine - Gastroenterology, U Penn, Philadelphia, PA, ¹¹Transplant Nephrology, U Penn, Philadelphia, PA
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…
2020 American Transplant Congress
Process Matters: Factors in Refusing Solid Organ Donation by African Americans
L. A. Siminoff¹, G. P. Alolod¹, H. M. Gardiner¹, R. D. Hasz², P. A. Mulvania², M. Wilson-Genderson¹
¹Social and Behavioral Sciences, Temple University, Philadelphia, PA, ²Gift of Life Donor Program, Philadelphia, PA
*Purpose: With approximately 25 African Americans (AAs) dying weekly while awaiting a transplantable organ, this study compares the experiences of AA families who authorized donation…
2020 American Transplant Congress
Utilization of Kidneys with Microthrombi and Acute Kidney Injury
W. De Faria, E. Shipman, G. Ciancio, G. Guerra
Miami Transplant Institute, Miami, FL
*Purpose: Kidneys continue to be discarded for reasons such as surgical damage, high kidney donor profile index (KDPI), prolonged cold ischemia time, and acute kidney…
2020 American Transplant Congress
Multi- National Survey among Nephrologists and Transplant Surgeons about the Suitability and Acceptance of the Marginal Live Kidney Donors with Family History of Kidney Disease
Z. Arabi¹, S. Kaysi², A. Altheaby¹, E. Elhassan¹, M. Bukhari³, A. Mateen¹, A. Hamad⁴
¹KAMC, Riyadh, Saudi Arabia, ²CHR Orleans, Orleans, France, ³Taif University, Taif, Saudi Arabia, ⁴The Regional Medical Center, Orangeburg, SC
*Purpose: Kidney transplantation from a living donor is the best treatment option for End Stage Kidney Disease. Considering the shortage of available organs, transplant centers…
2020 American Transplant Congress
Double or Nothing: Reducing Organ Discards by Preemptive Dualization of ‘at Risk’ Single Kidney Offers
S. K. Patel¹, S. Chang², R. Plews¹, R. Sussman³, D. Disante³, D. Schuster¹, P. Nguyen¹, R. Lopez-Soler⁴, D. Conti¹
¹Kidney Pancreas Transplant Division, Albany Medical Center, Albany, NY, ²Nephrology, University at Buffalo, Buffalo, NY, ³CDT, Albany Medical Center, Albany, NY, ⁴Renal Transplant Program, Edward Hines Jr., VA Medical Center, Chicago, IL
*Purpose: The purpose of this study is to evaluate a protocol designed to (1) enhance early identification of “at risk” single kidney offers (SKO) and…
2020 American Transplant Congress
Marginal Not So Marginal Anymore: Time for New Definitions for “Marginal” Allografts in Liver Transplantation?
T. Zhang¹, J. Dunson¹, F. Kanwal², T. Galvan², J. Vierling², C. O'Mahony², J. Goss², A. Rana²
¹Medical Student, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, TX
*Purpose: We examined time trends in the outcomes of patients who received marginal liver allografts defined on the basis of the Donor Risk Index [DRI]…
2020 American Transplant Congress
Age-Enhanced Transplant Vasculopathy Associates with Impaired Vascular Mitophagy
M. Blin¹, D. Tyrrell¹, S. Wood¹, D. Farris¹, S. G. Tullius², D. R. Goldstein¹
¹Micro and Immunology/Internal Medicine, University of Michigan, Ann Arbor, MI, ²Transplant Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Donor aging leads to increased chronic allograft vasculopathy (CAV) for unclear reasons. Here, we investigated whether impaired alterations in mitophagy, a mechanism to remove…
2020 American Transplant Congress
Liver Transplant with Donation after Cardiac Death versus Donation after Brain Death Donors: Survival and Outcomes at 10 Years
O. Haque¹, E. Roth², A. Fleishman¹, K. Khwaja¹
¹Surgery, Beth Israel Deaconess Medical Center, Boston, MA, ²Harvard Medical School, Boston, MA
*Purpose: This observational study utilizes the SRTR database to assess liver transplant outcomes after Donation after Cardiac Death (DCD) versus Donation after Brain Death (DBD)…
2020 American Transplant Congress
Impact of Liver Graft Preservation Methods on the Gut Microbiome and Metabolome
G. A. Cresci¹, N. Sangwan², A. Simioni³, Q. Liu³, C. Quintini³
¹Pediatric Gastroenterology and Inflammation & Immunity, Cleveland Clinic, Cleveland, OH, ²Lerner Research Institute, Cleveland Clinic, Cleveland, OH, ³Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Normothermic ex-vivo liver perfusion (NEVLP) is a powerful platform for organ preservation and assessment. It induces metabolic reactivation that potentially helps clear accumulated toxic…
2020 American Transplant Congress
A Simple Scoring System for Risk Stratification in Liver Transplantation after Donor Liver Biopsy
J. A. Steggerda, M. B. Bloom, K. Mahendraraj, T. Ramos, T. Todo, T. V. Brennan, N. N. Nissen, A. S. Klein, I. K. Kim
Surgery, Cedars-Sinai Medical Center, Los Angeles, Los Angeles, CA
*Purpose: Macrosteatosis (MaS) identified on donor liver biopsy (DLBx) influences organ utilization but alone is not predictive of outcomes following liver transplantation (LT). Here we…